Tag: KDC-MN-1532

  • Mirabegron

    Selective beta-3 adrenergic receptor agonist with secondary CYP2D6 inhibitory activity

    A selective beta-3 adrenoceptor agonist developed by Astellas Pharma as the first non-antimuscarinic oral treatment for overactive bladder, distinguished from the antimuscarinic drug class by its distinct receptor mechanism, favorable dry mouth and cognitive side-effect profile, moderate CYP2D6 inhibitory activity, and emerging research interest in brown adipose tissue thermogenesis, metabolic disease, and oncology.

    Abstract

    Mirabegron (YM-178) is a selective beta-3 adrenergic receptor (beta-3-AR) agonist approved in over 40 countries for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Developed by Astellas Pharma and first approved in Japan in 2011 and by the United States Food and Drug Administration in June 2012, mirabegron represented a paradigm shift in OAB pharmacotherapy as the first non-antimuscarinic agent approved for the indication, offering clinically meaningful efficacy with a substantially lower incidence of the dry mouth, constipation, and cognitive impairment that limit long-term adherence to antimuscarinic agents such as oxybutynin, tolterodine, solifenacin, darifenacin, and fesoterodine. The compound activates beta-3 adrenergic receptors on detrusor smooth muscle cells, producing cyclic adenosine monophosphate (cAMP)-mediated relaxation of the bladder wall during the storage phase and thereby increasing functional bladder capacity without impairing voiding contractility. The compound is also a moderate inhibitor of cytochrome P450 2D6 (CYP2D6), producing clinically relevant increases in systemic exposure to CYP2D6 substrates including metoprolol, desipramine, and thioridazine, a property that requires attention in polypharmacy contexts. The safety profile in pooled clinical trial data and in extensive postmarketing surveillance confirms a low incidence of dry mouth (comparable to placebo), with the principal treatment-emergent adverse events being hypertension (7 to 11 percent), nasopharyngitis, urinary tract infection, and headache. Cardiovascular safety analyses, including a multinational non-interventional cohort study, have not identified increased risk of major adverse cardiovascular events relative to antimuscarinic comparators. Beyond the established OAB indication, mirabegron has attracted substantial research interest as a pharmacological activator of brown adipose tissue (BAT) thermogenesis through beta-3-AR-mediated stimulation of uncoupling protein 1 (UCP1) expression. Chronic mirabegron treatment in human subjects has been shown to increase BAT metabolic activity, resting energy expenditure, high-density lipoprotein cholesterol, adiponectin, and insulin sensitivity, positioning the compound as a research tool for metabolic disease and obesity pharmacology. Additional preclinical research has demonstrated antitumor activity through adipose tissue browning and modulation of the tumor microenvironment. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.